genOway Logo

genOway

Develops custom genetically modified preclinical models for biopharma and academic research.

ALGEN | PA

Overview

Corporate Details

ISIN(s):
FR0004053510
LEI:
969500HMHUPR3KYXUT19
Country:
France
Address:
31 RUE SAINT JEAN DE DIEU, 69007 LYON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Founded in 1999, genOway is a global biotechnology company specializing in the design and development of genetically modified preclinical models. The company provides a comprehensive portfolio of mouse, rat, and cell line models to bio-pharmaceutical companies, life sciences organizations, and academic researchers. genOway offers both a catalog of validated models and customized model creation services tailored to specific scientific questions. Its core mission is to enhance the predictability of preclinical research, helping to bridge the gap between laboratory findings and clinical success for new therapies. The company leverages deep expertise in biological physiology and a collaborative approach to deliver solutions for clients, including many of the world's top pharmaceutical companies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-27 17:55
Earnings Release
Résultats annuels 2024 - genOway accélère le déploiement de son plan stratégiqu…
French 223.0 KB
2025-01-20 18:00
Earnings Release
Croissance solide de +10% de l'activité en 2024 à 22,1 M EUR
French 194.7 KB
2024-11-04 18:00
Regulatory News Service
Lutte contre l'obésité et les maladies métaboliques : les modèles humanisés de …
French 130.1 KB
2024-09-23 18:00
Earnings Release
Résultats semestriels 2024 conformes avec les objectifs du nouveau plan stratég…
French 207.7 KB
2024-07-18 18:00
Earnings Release
Un 1er semestre 2024 en croissance de +15%, de bon augure en pleine mise en oeu…
French 176.4 KB
2024-07-04 18:00
Business and Financial Review
Bilan semestriel du contrat de liquidité
French 355.0 KB
2024-06-25 17:55
Regulatory News Service
Solide démarrage du développement de la coentreprise genOway Shanghai en Chine
French 198.0 KB
2024-03-28 18:00
Regulatory News Service
Organisation d'une visioconférence destinée aux investisseurs individuels
French 128.0 KB
2024-03-26 17:45
Earnings Release
Résultats annuels 2023 : genOway poursuit sur sa lancée avec une croissance de …
French 219.5 KB
2024-02-09 11:00
Regulatory News Service
genOway fait son entrée au palmarès 2024 des 500 ' Champions de la croissance '
French 129.5 KB
2024-01-22 08:00
Regulatory News Service
genOway participe à la 1ère édition du Retail Day organisée par Euroland Corpor…
French 125.7 KB
2024-01-16 18:05
Board/Management Information
genOway dévoile Route 50+, son nouveau plan stratégique visant à bâtir un leade…
French 198.9 KB
2024-01-16 18:00
Earnings Release
genOway dépasse le seuil des 20 M EUR de chiffre d'affaires en 2023, porté par …
French 176.3 KB
2023-11-22 18:00
Report Publication Announcement
Initiation de la couverture du titre genOway par Euroland Corporate
French 100.2 KB
2023-10-17 18:00
M&A Activity
genOway crée une coentreprise à Shanghai avec pour objectif de devenir le parte…
French 141.9 KB

Automate Your Workflow. Get a real-time feed of all genOway filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for genOway via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-17 N/A Other Sell 1,700 8,160.00 EUR
2023-12-15 N/A Other Sell 5,000 22,000.00 EUR
2023-11-23 N/A Other Sell 500 2,100.00 EUR
2023-10-23 N/A Other Sell 100 390.00 EUR
2023-09-25 N/A Other Buy 5,000 20,000.00 EUR
2023-05-04 N/A Other Buy 60,000 222,000.00 EUR
2023-05-02 N/A Other Sell 20,000 74,000.00 EUR

Peer Companies

Company Country Ticker View
CARTA HOLDINGS, INC. Logo
Digital marketing firm offering ad platforms and integrated solutions to empower businesses.
Japan 3688
Celyad Oncology SA Logo
Clinical-stage biotech developing CAR T therapies for solid and blood cancers.
Belgium CYAD
CENTAUR MEDIA PLC Logo
Provides business intelligence, learning, and consultancy for marketing & legal professionals.
United Kingdom CAU
Cereno Scientific AB Logo
Develops epigenetic therapies for rare cardiovascular and pulmonary diseases.
Sweden CRNO
CERES INC. Logo
Develops online media platforms connecting consumers with advertisers through a rewards system.
Japan 3696
Chabiotech Co.,Ltd. Logo
Develops cell/gene therapies and offers CDMO, biobanking, and genomics services for rare diseases.
South Korea 085660
An Ad-Tech firm providing digital marketing, SEO, social media, and creative ad solutions.
South Korea 351870
Ch. Charilaou Group Plc Logo
A tour operator selling travel packages and developing online reservation platform solutions.
Cyprus CHCH
Creates data-driven, integrated marketing and connected experiences for global brands.
South Korea 030000
Chiome Bioscience Inc. Logo
Clinical-stage biotech developing therapeutic antibodies and providing R&D services to partners.
Japan 4583

Talk to a Data Expert

Have a question? We'll get back to you promptly.